The reporter learned from the national medical security work conference held recently: the first five batches of national centralized procurement of drugs and coronary stents will save nearly 170 billion yuan in drug costs in 2021, and the national medical insurance negotiated drugs will benefit patients 1.4% in 2021 100 million person-times and 150 billion yuan of burden reduction.
In November 2020, the state organized the centralized procurement of high-value medical consumables for the first time, and the average price of coronary stents dropped from about 13,000 yuan to about 700 yuan, a drop of more than 90%. Landed on January 1, 2021. Data shows that in 2021, medical institutions will use more than 1.5 million selected products, and this alone will reduce the burden of patient expenditure by more than 6.5 billion yuan.
In 2021, the average price of 42 special insulin collection products will be reduced by 48%, and the average price of artificial hip joint and knee joint collection products will be reduced by 82%. It is expected to benefit nearly 11 million patients and reduce the burden of nearly 30 billion yuan per year; The 2021 version of the drug list has increased to 2,860 varieties, and the average price of 67 negotiated drugs has been reduced by 62%. All these policies will be implemented this year, allowing more people to use high-quality and low-cost pharmaceutical products. (Reporter Sun Xiuyan)